Navigation Links
FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial

SEATTLE, March 10, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL") following discussions with the  U.S. Food and Drug Administration's (the "FDA") Division of Hematologic Products (the "DHP") .  The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy, utilizing progression free survival ("PFS") and Overall Survival ("OS")as co-primary endpoints of the study. The PIX-R trial, is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant. During its discussions with the DHP the Company was advised that only OS would be acceptable for a formal Special Protocol Assessment ("SPA") agreement, however the DHP noted that the Company could conduct a study utilizing PFS along with OS as co-primary endpoints which would be an acceptable design outside of the formal SPA process. Regulatory acceptability will depend on the magnitude of the difference between the trial study arms as well as a risk and benefit analysis.

"CTI has worked with the DHP since August on an appropriate clinical trial design that may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of an appeal of CTI's new drug application for pixantrone based on the PIX 301 trial at the FDA's Office of New Drugs," stated James A. Bianco, M.D., CEO of Cell Therapeutics.

"We believe that pre-clinical data and results from a randomized clinical trial have already demonstrated synergy exists between pixantrone and rituximab when they are used in combination. We believe that pixantrone administered as a single agent had a significant effect on prolonging PFS with an accompanying trend in OS in the PIX 301 trial. Given these results and the similar patient population in the PIX-R trial, including the choice of comparator regimen, we believe this trial has the potential to establish the clinical benefit of pixantrone in this patient group to fulfill an important unmet medical need," added Dr. Bianco.

In December 2010, CTI submitted a formal appeal to the FDA's Office of New Drugs ("OND") in the FDA's Center for Drug Evaluation and Research regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone.  The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") patients. CTI recently met with the OND to discuss the appeal. The OND requested, and CTI plans to supply the FDA with, additional analyses from the PIX 301 trial. CTI expects a decision regarding its appeal early in the second quarter of 2011.

In Europe, the Marketing Authorization Application (the "MAA") for pixantrone as monotherapy for patients with relapsed or refractory aggressive NHL is currently under review by the European Medicines Agency (the "EMA") based on the pixantrone (PIX 301) phase III study results.  

PIX-R TRIAL DesignThe PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory DLBCL or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are PFS and OS with secondary endpoints including overall response rate (ORR equals complete responses plus partial responses), complete response rate and safety. To date, over 100 large U.S.-integrated oncology sites have signed up to participate in the PIX-R trial and 40 of such sites are preparing to initiate enrollment when the trial begins, which may be as early as later this month.   CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial. CTI plans to perform the primary analysis of PFS first, which, depending on the outcome of CTI's appeal with the OND, could serve as the basis for resubmission of the NDA for pixantrone under accelerated approval regulations. Co-primary endpoints allow the analysis and reporting of PFS without a statistical penalty while the trial data matures and before OS is analyzed.  OS, as the co-primary endpoint, will be analyzed at the end of the trial.

About PixantronePixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II, but unlike anthracyclines,  rather than intercalation with DNA,pixantrone alkylates DNA and forms stable DNA adducts with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory diffuse large NHL and/or other tumors as determined by the FDA and/or the EMA, whether alone or in combination with rituximab, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI may not initiate a new clinical trial for pixantrone in 2011, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, that CTI's appeal may not be successful, that the EMA may not approve CTI's MAA after review, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.Media Contact:Dan Eramian T: 206.272.4343C: 206.854.1200E: deramian@ctiseattle.comInvestors Contact:Ed BellT: 206.272.4345Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: Information Contact:T: 800.715.0944E:

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
2. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
3. Savient Pharmaceuticals Provides Business Update
4. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
5. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
7. Generex Provides Additional Details for October 21st Live Video Webcast
8. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
9. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
10. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
11. NeoStem Provides Second Quarter Update
Post Your Comments:
(Date:6/23/2017)... , ... June 23, 2017 , ... Biova, LLC., the ... has joined Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific ... has served as the Chief Technical and Scientific Officer of four major global companies ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist ... have been selected as this year’s recipients of two top awards from SPIE, ... along with other honorees to accept their awards at a banquet in San Diego, ...
(Date:6/23/2017)... ... 2017 , ... The Academy of Model Aeronautics (AMA), the ... (UAA), the unifying voice for collegiate aviation education, are launching a joint UAS ... success through a STEM-based education platform. , Much like the program currently available ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces ... Reinhardt to manage the new site. , Tim has 25 years of pharmaceutical ... recent role as the Director of Manufacturing and Supplier Quality Assessment. This ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
Breaking Biology News(10 mins):